Floatz Rating
C39/100
Confidence
Indicative
Sponsor
HiFiBiO Therapeutics
Modality
monoclonal_antibody
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05238883CT.gov A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Mesothelioma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Emunkitug (this asset) | HiFiBiO Therapeutics | P1 | C · 39 |
| Cyclophosphamide | National Cancer Institute (NCI) | P2 | BB |
| Nivolumab | Orion Corporation, Orion Pharma | P2 | B |
| Fludarabine | National Cancer Institute (NCI) | P2 | B |
| Pembrolizumab | Genmab | P2 | B |
| Fludeoxyglucose | National Cancer Institute (NCI) | P2 | B |
| 18f-fspg | Andrei Iagaru | P2 | B |
| Tislelizumab | HiFiBiO Therapeutics | P2 | CCC |
| Irinotecan | Genmab | P1/2 | CCC |
+42 more in the Mesothelioma cohort
Other indications for Emunkitug
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Testicular Germ Cell Tumor | — | P1 | CC · 43 |
| Sarcoma | — | P1 | C · 39 |
| Gastric Cancer | — | P1 | C · 37 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Emunkitug in Mesothelioma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/emunkitug-mesothelioma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →